Finnegan is pleased to share that the firm is nominated in eight categories for Life Sciences IP Review's 2026 LSPN Awards. The awards recognize individuals and organizations that are shaping the future of pharmaceutical and biotech patent protection. The ceremony will take place in Boston at the The Hyatt Regency (Ave De Lafayette) on April 30, 2026. The firm is nominated in the following categories:
- Best in Patent Portfolio Management
- Excellence in Patent Licensing and Transactions
- IP Boutique of the Year Life Sciences
- IP Firm of the Year
- Life Sciences IP Litigation Firm of the Year
- Life Sciences Patent Strategy Firm of the Year
- Life Sciences Prosecution Firm of the Year
- Patent Prosecutor of the Year Award - Jeffrey Jacobstein
Finnegan's Life Sciences practice reflects the intersection of the law, science, and technology. The firm's team of experienced attorneys and professionals brings deep insight into the legal, technical, regulatory, and commercial challenges facing life sciences innovators. Our professionals hold advanced degrees in disciplines such as biology, chemistry, biochemistry, medicine, pharmacology, biomedical engineering, and electrical engineering, and include attorneys with significant experience in brand management and protection. We counsel clients across the full life cycle of intellectual property protection, from litigating high‑value products and developing strategic patent portfolios to aligning patent and regulatory approaches. Our team also conducts portfolio and landscape analyses, structures licensing programs, performs due diligence, handles post‑grant proceedings, and provides comprehensive trademark, branding, and advertising protection.
